|
.................................... Search the net .................................... |
Paediatric Pulmonology and Allergology
2008 April, Vol. XI, No. 1 (3884-3891)
IN-PATIENT ANTIMICROBIAL MANAGEMENT OF CYSTIC FIBROSIS IN LITHUANIA
Viktorija Pavydiene1, Sigitas Dumcius1, 2, Arunas Valiulis1, 2
1Vilnius University Clinic of Paediatrics & 2Vilnius City University Hospital, Antakalnio Str. 57, LT-10207 Vilnius, Lithuania
Patients with cystic fibrosis have pulmonary system damage due to chronic bacterial infection and strong inflammatory response of the body. A number of pulmonary exacerbations determines the course of the disease and has a major impact on the prognosis of patients. It is very important to recognize symptoms and signs of an exacerbation as early as possible and prescribe compound treatment. Antibacterial therapy is one of the most important part of this treatment. Although the main strategies against bacterial pathogens and lung inflammation have been presented in the European consensus report antimicrobial management of pulmonary infections of cystic fibrosis patients may vary in different clinics. This article is devoted to retrospective analysis of 137 cases of children with cystic fibrosis exacerbation. All children were hospitalized in Vilnius University City Hospital during the period 1997–2007. The patients with cystic fibrosis exacerbation most frequently complained with cough (96,3%) and dyspnoea (43,1%). The most common clinical signs were fever and crackles. S. aureus (52,2%) and P. aeruginosa (27,2%) were the most common organisms isolated from sputum of patients with cystic fibrosis exacerbation. A lot of children (73%) were treated with combination antibacterial therapy. Intravenous antibiotic use was preferred (87,5%). The most often combination was penicillin and aminoglycoside (58,3% of cases).